GnRH Antagonist: a New and an Effective Way of Treatment of Advanced Prostate Cancer

Overview

Journal Indian J Surg Oncol

Specialty Oncology

Date 2022 Sep 19

PMID 36118411

Authors

Bertrand Tomabal

S K Raghunath

N Srivatsa

V H Nagaraj

Affiliations

Soon will be listed here.

Abstract

Castration remains the mainstay of treatment in the management of metastatic prostate cancer. Medical castration plays an important role in a majority of these patients. Gonadotropin releasing hormone (GnRH) agonists have been commonly used hitherto to achieve medical castration. Arrival of GnRH antagonists have opened a new approach in the management of these patients with distinct drug-related and cancer-related benefits including prevention of microsurges and reduction in cardiovascular complications. This article elucidates the mechanism of action of GnRH antagonists along with its clinical advantages and demerits.

Citing Articles

Safety, Pharmacokinetic and Pharmacodynamic Evaluation of Teverelix for the Treatment of Hormone-Sensitive Advanced Prostate Cancer: Phase 2 Loading-Dose-Finding Studies.

MacLean C, Ulys A, Jankevicius F, Saladzinskas Z, van Os S, Larsen F Medicina (Kaunas). 2023; 59(4).

PMID: 37109639 PMC: 10146264. DOI: 10.3390/medicina59040681.

References

Smith M, Klotz L, van der Meulen E, Colli E, Tanko L . Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol. 2011; 186(5):1835-42. PMC: 3712275. DOI: 10.1016/j.juro.2011.07.035. View

Carter N, Keam S . Degarelix: a review of its use in patients with prostate cancer. Drugs. 2014; 74(6):699-712. DOI: 10.1007/s40265-014-0211-y. View

Ozono S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y . The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. Jpn J Clin Oncol. 2012; 42(6):477-84. DOI: 10.1093/jjco/hys035. View

Klotz L, Boccon-Gibod L, Shore N, Andreou C, Persson B, Cantor P . The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008; 102(11):1531-8. DOI: 10.1111/j.1464-410X.2008.08183.x. View

Engel J, Schally A . Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007; 3(2):157-67. DOI: 10.1038/ncpendmet0399. View

Frampton J, Lyseng-Williamson K . Degarelix. Drugs. 2009; 69(14):1967-76. DOI: 10.2165/10484080-000000000-00000. View

de la Rosette J, Davis 3rd R, Frankel D, Kold Olesen T . Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer. Int J Clin Pract. 2011; 65(5):559-66. DOI: 10.1111/j.1742-1241.2011.02637.x. View

Pinski J, Yano T, Miller G, Schally A . Blockade of the LH response induced by the agonist D-Trp-6-LHRH in rats by a highly potent LH-RH antagonist SB-75. Prostate. 1992; 20(3):213-24. DOI: 10.1002/pros.2990200306. View

Persson B, Olesen T, Jensen J . Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology. 2009; 90(3):235-44. DOI: 10.1159/000228832. View

10.

Smith M, Klotz L, Persson B, Olesen T, Wilde A . Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol. 2010; 184(6):2313-9. PMC: 3047399. DOI: 10.1016/j.juro.2010.08.012. View

11.

Broqua P, Riviere P, Conn P, Rivier J, Aubert M, Junien J . Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther. 2002; 301(1):95-102. DOI: 10.1124/jpet.301.1.95. View

12.

Gittelman M, Pommerville P, Persson B, Jensen J, Olesen T . A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol. 2008; 180(5):1986-92. DOI: 10.1016/j.juro.2008.07.033. View

13.

van Poppel H, Tombal B, de la Rosette J, Persson B, Jensen J, Olesen T . Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol. 2008; 54(4):805-13. DOI: 10.1016/j.eururo.2008.04.065. View

14.

Shore N . Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol. 2013; 5(1):11-24. PMC: 3547532. DOI: 10.1177/1756287212461048. View

15.

Sharma O, Weinbauer G, Behre H, Nieschlag E . The gonadotropin-releasing hormone (GnRH) agonist-induced initial rise of bioactive LH and testosterone can be blunted in a dose-dependent manner by GnRH antagonist in the non-human primate. Urol Res. 1992; 20(5):317-21. DOI: 10.1007/BF00922743. View

16.

Crawford E, Shore N, Moul J, Tombal B, Schroder F, Miller K . Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology. 2014; 83(5):1122-8. DOI: 10.1016/j.urology.2014.01.013. View

17.

Albertsen P, Klotz L, Tombal B, Grady J, Olesen T, Nilsson J . Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2013; 65(3):565-73. DOI: 10.1016/j.eururo.2013.10.032. View